Published in AIDS Weekly, March 23rd, 2009
As one example of how this process works, the FDA asked CytoDyn to conduct a laboratory experiment to quantify the effect of Cytolin® on HIV. In its response, the Company explained that an immune modulator cannot have a direct effect on a virus making what the FDA requested a scientific impossibility. Rather, the reduction in HIV levels consistently observed in patients treated with Cytolin® is due to improved functioning of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.